NCT05938075View on ClinicalTrials.gov

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

PHASE1CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

July 25, 2024

Study Completion Date

July 25, 2024

Conditions
SARS-CoVSARS-CoV-2
Interventions
BIOLOGICAL

VXCO-100

Sterile suspension for injection

BIOLOGICAL

COVID-19 mRNA vaccine

Sterile suspension for injection

Trial Locations (2)

Unknown

Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital, Johannesburg

HIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Botha’s Hill

All Listed Sponsors
collaborator

Medical Research Council, South Africa

OTHER

lead

Vaccine Company, Inc.

INDUSTRY